Drugs / Kleb4V
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04959344 | Jul 2021 → Sep 2022 | Klebsiella infectious disease | LimmaTech Biologics AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kleb4V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04959344 ↗ |
| Route | Intramuscular | “Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart” NCT04959344 ↗ |